FDA Rejects Dor Biopharma’s OrBec For GI Graft-Versus-Host Disease
This article was originally published in The Pink Sheet Daily
Executive Summary
In a “not approvable” letter, agency requests additional clinical trial data to show the drug is safe and effective.